(Alliance News) - Genedrive PLC said on Tuesday that the UK National Institute of Clinical Excellence gave the company's MT-RNR1 hearing loss test a new Medtech Innovation Briefing.
Shares in Genedrive were up 18% at 29.50 pence on Tuesday in London.
The Manchester, England-based molecular diagnostics company explained that MIBs are designed to support National Health Service, social care commissioners and staff who are considering using new medical devices and technologies.
They do not make recommendations but contain a summary of the technology, published evidence, health economic overview, and expert options on the advantages and disadvantages.
Genedrive explained the briefing was an important step to increase awareness in the NHS of new innovation and ultimately support adoption in the UK.
The MT-RNR1 test screens infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given certain antibiotics.
Chief Executive David Budd said: "We are grateful to NICE for their engagement and interest in our innovative technology and pleased that the Genedrive MT-RNR1 test was selected for a MIB review. This NICE MIB documentation, our cooperation with Inspiration Healthcare PLC and the publication of the PALOH study results are all important components needed to successfully promote our innovative test for antibiotic induced hearing loss screening."
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Genedrive (GDR)